This week on "The Readout LOUD," we discuss Viking Therapeutics' obesity flop and dish on the growing "pharm to table" movement.

Pedersen and Maggie Fick COPENHAGEN (Reuters) -As Novo Nordisk's sales of its blockbuster weight-loss drug Wegovy boomed, the ...

As Novo Nordisk's sales of its blockbuster weight-loss drug Wegovy boomed, the Danish drugmaker raced to expand manufacturing capacity and sales outreach with a hiring spree that almost doubled staff ...

No one stays on top forever. It’s a lesson that Ozempic maker Novo Nordisk may be painfully learning about. The Danish ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Serena Williams has joined telehealth company Ro as a celebrity ambassador for their weight-loss treatments. Williams will star in ads for GLP-1 medications and share her health journey post-pregnancy ...

The United States and European Union on Thursday released new details of their trade framework, providing clarity on tariffs for sectors including pharmaceuticals, semiconductors, and autos after ...

Demand for Novo Nordisk A/S’s weight-loss blockbuster Wegovy is getting a boost in the UK from an unexpected corner: ...

In people with recently diagnosed type 2 diabetes and no prior cardiovascular disease, self-reported physical activity ...

The pharma giant has almost doubled the size of its workforce over the last five years but is now looking to tighten cost controls amid challenges in the obesity-drug market.

RFK Jr. has his sights set on increasing oversight and enforcement against drugmakers that run afoul of advertising laws.

Viking Therapeutics' stock drops 40% despite strong Phase 2 weight-loss drug results. See here to know why I remain ultra ...